Articles by Nichole Tucker
CLL treatments are advancing—hear Dr. Wierda discuss resistance, remission, and future therapies on the HemOnc Pulse.
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
Dr. Hira Mian reviews selinexor, talquetamab, and emerging trispecifics shaping the future of multiple myeloma care.
Exploring treatment sequencing, prior therapy impact, and targeted approaches in lower-risk myelodysplastic syndromes.
Targeted therapies reshape CLL treatment, shifting focus from age to comorbidities, and patient preferences.
Dr. Vose outlined the biggest takeaways from the CLL session at the 2025 Pan Pacific Leukemia Conference.
Experts spotlight promising new CAR T-cell and bispecific therapies shaping the future of myeloma treatment.
JNJ-5322 shows 100% response at RP2D in anti-BCMA/GPRC5D–naïve multiple myeloma, according to a phase 1 study.
Explore expert insights on bispecifics, CAR T-cell therapy, and emerging regimens for B-cell lymphomas.
Hematology/oncology fellow Joseph Van Galen, MD, is investigating the mechanisms behind immune-related adverse events.
Next-gen BCL-2 inhibitors show promise in RRMM as venetoclax struggles with OS in phase 3 BELLINI study.
Linvoseltamab earns FDA nod for RRMM with 70% ORR, monthly dosing, and lower CRS than other bispecifics.
Ruxolitinib shows durable benefit and long-term safety in steroid-refractory chronic GVHD, REACH3 finds.
Dr. Amir Fathi discusses oral regimens and future AML therapy trends in this Editor’s Special of The HemOnc Pulse.
FDA approves tafasitamab plus R2 for relapsed FL, showing 57% reduced risk of progression in phase 3 inMIND trial.
Bexmarilimab shows promising responses in high-risk MDS, with up to 85% ORR in the BEXMAB phase 2 study.
Luspatercept shows longer survival and transfusion independence in ESA-naïve lower-risk MDS, COMMANDS trial.
Vinayak (Vinay) Prasad, MD, MPH, has been appointed director of the FDA Center for Biologic Evaluation and Research.
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Cilta-cel improves PFS and OS in len-refractory MM across subgroups, including high-risk cytogenetics, per CARTITUDE-4.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.